This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna Collaborates to Support Coronavirus Vaccine Supply
by Zacks Equity Research
Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
by Kinjel Shah
Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
by Zacks Equity Research
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $34.03, moving -1.39% from the previous trading session.
Is it the Right Time to Invest in Momentum ETFs? Let's Explore
by Sweta Jaiswal, FRM
Here we discuss whether it will be wise to invest in momentum ETFs now as the U.S. manufacturing is showing signs of recovery along with improvements in the jobs market.
3 Diverse Stocks to Buy Now for Second Half Coronavirus Immunity & Growth
by Benjamin Rains
A look at three stocks from completely different economic sectors that are poised to grow during the second half of 2020, despite continued coronavirus economic uncertainty...
Moderna Shares Lose Momentum After Meteoric Rise: Here's Why
by Zacks Equity Research
The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
by Sweta Jaiswal, FRM
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
by Kinjel Shah
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
4 ETF Investing Styles for Q3
by Sanghamitra Saha
At the start of Q3, the operating and investing backdrop looks mixed. The second wave of virus contagion has already hit the market and threatening the speed of recovery while several economic data points are coming in upbeat thanks to the reopening.
Pfizer Reports Encouarging Data From Coronavirus Program
by Zacks Equity Research
Pfizer (PFE) announces promising preliminary data on a vaccine candidate from its early-stage coronavirus program under which it is developing four mRNA-based vaccine candidates.
Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
by Zacks Equity Research
An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.
Stock Market News for Jul 2, 2020
by Zacks Equity Research
The Nasdaq and the S&P 500 closed higher on Wednesday as investors focused on signs of economic recovery and better than expected economic data.
Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety
by Benjamin Rains
All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...
Pfizer's sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU Nod
by Zacks Equity Research
The FDA approves Pfizer (PFE) and Merck KGaA's sBLA for Bavencio as a first-line maintenance therapy for metastatic urothelial carcinoma. Daurismo gets the EU nod for acute myeloid leukemia.
ADP Gains 2.37M Jobs, Pfizer's COVID Drug Passes Test
by Mark Vickery
ADP's private sector jobs gained below the 2.5 million expected for June, but Pfizer's drug candidate takes the next step forward.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
FDA Issues Guidance for Coronavirus Vaccine Developers
by Kinjel Shah
Around a dozen companies are developing a vaccine for the deadly coronavirus disease.
3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety
by Benjamin Rains
Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $32.64, marking a +1.87% move from the previous day.
Sarepta Completes Rolling NDA Submission for New DMD Therapy
by Zacks Equity Research
Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Merck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda for recurrent or metastatic cutaneous squamous cell carcinoma, a form of skin cancer, gets approval from the FDA.